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Much of the understanding of hypertensive pulmonary thelial structure and function that could result in impaired 
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nary hypertension. The three subtypes of primary pul- embolic pulmonary arteriopathy, or more properly throm- 
monary hypertension, plexogenic pulmonary arteriopathy, botic pulmonary hypertension, appears to be the result of 
thromboembolic pulmonary hypertension 
and venoocclusive disease. have served as 
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nary arteriopathy is associated with abnormalities of endo- 
’ 9 8 9 liai injury, s;ch-& that which occurs with 
hypoxic lung disease or mitral stenosis, appears more 
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Pulmonary hypertension is a relatively common sequela of a 
variety of cardiac and lung diseases. Interest in pulmonary 
hypertension has more recently been stimulated by identiti- 
cation of the rare disease known as “primary pulmonary 
hypertension” in which high pulmonary artery pressure and 
pulmonary vascular resistance from unknown causes pro- 
duce chronic right heart failure and lead to death (I). 
Physicians have extrapolated from observations regarding 
primary pulmonary hypertension to pulmonary hypertensive 
conditions in general. with respect to both pathophysiologic 
mechanisms and eff‘ective treatments. This review will high- 
light new da& that suggest a need to refocus OUI underaland- 
ing of the etiology of pulmonary hypertensive states and the 
basis of our therapeutic etforts. 
Primary 
Primary 
Pulmonary Hypertension: A Human 
Disease Model 
pulmonary hypertension serves ah a clinical 
model of “pure” pulmonary hypertension without an obvi- 
out secondary cause. Although primary pulmonary hyper- 
tension was originally described by Dresdale et al. (2) in 
IYS I. the most widely publicized description of the condition 
came from a World Health Organization symposium on the 
dl\ea5e in Geneva in I973 (3). At that time. three subtypes of 
primary pulmonary hypertension were described: plexo- 
genie pulmonary arteriopathy. recurrent pulmonary throm- 
hoernholi\m and pulmonary venoocclusive disease. Little is 
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known about pulmonary venoocclusive disease, as it is 
clearly the most rare form of primary pulmonary hyperten- 
sion, occurring in approximately 5% of all cases of primary 
pulmonary hypertension (4). The other two histologic sub- 
types are more common and occur in both primary and 
secondary forms of pulmonary hypertension. 
Plexogenic Pulmonary Arteriopathy 
Etiology. The histologic features of plcxogenic pulmo- 
nary arteriopathy are medial hypertrophy. intimal prolifera- 
tion and plexiform lesions involving the pulmonary arterioles 
that are believed to be a result of intense vasoconstriction 
(3,5.6). Autopsy findings in patients with primary pulmonary 
hypertension vary from medial hypertrophy with intimal 
proliferation to the entire spectrum of these histologic 
changes. These findings suggest that medial hypertrophy is 
the earliest lesion, thus supporting the notion that primary 
vasoconstriction is the mechanism for plexogenic pulmonary 
arteriopathy (7). Reports that agents of the vasodilator type 
reduce pulmonary vascular resistance strengthened the con- 
cept that vasoconstriction was the underlying mechanism 
(&IO). It is important to recognize that plexogenic pulmo- 
nary arteriopathy is not pathognomonic for primary pulmo- 
nary hypertension, but exists in other forms of pulmonary 
hypertension. suggesting that vasoconstriction is occurring 
in secondary forms of pulmonary hypertension as well (5.7). 
Therefore, pulmonary hypertension arising from post- 
tricuspid left to right intracardiac shunts (e.g.. ventricular 
septal defect. patent ductus arteriosus) suggests that reactive 
pulmonary vasoconstriction is a response to increased pul- 
monary blood flow (1 I). 
The observation that collagen vascular diseases are asso- 
ciated with plexogenic pulmonary arteriopathy in the ab- 
sence of significant parenchymal lung disease suggests that 
some autoimmune mechanism may be stimulating pulmo- 
nary vascular smooth muscle (12-14). Liver cirrhosis of any 
etiology has also been associated with plexogenic pulmonary 
arteriopathy, leading to speculation that unmetabolized va- 
soactive compounds pass through the liver to the lung and 
produce pulmonary vasoconstriction, although these com- 
pounds have never been identified (15.16). Finally, aminorcx 
fumarate. an appetite suppressant drug with sympathomi- 
metic properties introduced in Europe in the 1960s. was 
shown to induce a dietary form of pulmonary hypertension, 
and it was presumed that aminorex produced pulmonary 
vasoconstriction (17). 
Hypothesis: plexogenic pulmonary arteriopathy is a result 
of endothelial cell injury that affects endothelial derived me- 
diators of smooth muscle. A closer look at the data on the 
mechanisms of the secondary forms of plexogenic pulmo- 
nary arteriopathy does not implicate pulmonary vascular 
smooth muscle as the culprit. but rather points toward the 
pulmonary vascular endothelium. With the recent discovery 
that endothelial derived mediators are the primary determi- 
nants of vascular smooth muscle tone, it is interesting to 
speculate that abnormalities of endothelial cell function may 
lead to pulmonary vasoconstriction (18). It is well estab- 
lished that the pulmonary vascular bed is a low resistance 
circuit, suggesting that the endothelium maintains a state of 
chronic smooth muscle relaxation, probably through the 
release of endothelial derived relaxing factors (lS21). Clin- 
ical data demonstrating that acetylcholine, which stimulates 
the release of endothelial derived relaxing factors, is often an 
effective pulmonary vasodilator in primary pulmonary hy- 
pertension suggests impaired function of the pulmonary 
vascular endothelial cell in these patients (22). The fact that 
other vasodilators that work directly on vascular smooth 
muscle are also effective in the same patients is consistent 
with a state of increased pulmonary vascular tone as a result 
of abnormal endothelial cell mediation (22). 
Pulmonary hypertension in congenital heart disease. His- 
tologic studies in patients with pulmonary hypertension 
associated with congenital heart defects have revealed ultra 
structural abnormalities in the endothelial cells that suggest 
heightened metabolic function (23). Recently, higher levels 
of von Willebrand factor antigenic activity were described in 
these patients (24). further implicating abnormal endothelial 
cell function in congenital heart disease with pulmonary 
hypertension. The fact that these abnormalities are present 
in patients irrespective of the severity of the pulmonary 
vascular disease, but not in patients with congenital heart 
disease without pulmonary hypertension, suggests that it 
may be an early feature in the development of the pulmonary 
hypertensive disease state. Because increased shear stress 
has been shown to be a mechanical factor that can cause 
endothelial cell disruption (25), it is now understandable why 
shunts appearing after development of the tricuspid valve 
commonly product pulmonary hypertension, whereas 
shunts appearing before development of the tricuspid valve 
(such as atrial septal defect and anomalous pulmonary 
venous drainage) with similar magnitudes of left to right 
shunting are much less likely (II). 
Aminorex-associated pulmonary hypertension. This con- 
dition is an interesting syndrome that resulted from the 
introduction of this appetite suppressant drug in Western 
Europe in the late 1960s (17). The incidence of patients who 
developed pulmonary hypertension after drug ingestion was 
approximately I in 1,000, suggesting that some underlying 
predisposition was also necessary. In addition, when the 
offending agent was withdrawn, although the condition of 
some patients improved, it remained the same in others and 
continued to worsen in many others. No animal model for 
aminorex-induced pulmonary hypertension has been pro- 
duced, possibly because some type of genetic susceptibility 
is also necessary. However, dietary pulmonary hypertension 
has been Induced in animals after the ingestion of crotolaria, 
an herbal plant found in tropical areas (26). Rats fed croto- 
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laria develop acute pulmonary hypertension within several 
weeks (27). Studies on the activity of the pulmonary endo- 
thelium and vascular smooth muscle in these animals (28) 
show that the initial effect of crotolaria is to cause acute 
endothelial cell injury that is followed by endothelial cell 
proliferation and several weeks later by an increase in 
vascular smooth muscle cells. Therefore, the basis of this 
form of dietary pulmonary hypertension that results in 
plexogenic arteriopathy also appears to be endothelial cell 
damage followed by smooth muscle cell proliferation. 
Collagen vascular disease. Although collagen vascular 
disease can cause plexogenic pulmonary arteriopathy, there 
has been no pathologic confirmation that acute cellular 
infiltration of the vascular smooth muscle is the earliest 
lesion (7). Rather, immune mediated injury of the endothe- 
lium is more likely. Patients with primary pulmonary hyper- 
tension have been shown to have high levels of antinuclear 
antibodies with a prevalence rate of approximately 40%~ (29). 
This prevalence rate puts primary pulmonary hypertension 
between rheumatoid arthritis and scleroderma with respect 
to the frequency of antinuclear antibodies in the spectrum of 
collagen vascular syndromes. Indeed, it does appear that 
some patients with primary pulmonary hypertension may 
have a forme fruste of collagen vascular disease confined to 
the lung. 
Role of pulmonary endothelial injury. Each of the second- 
ary causes of plexogenic pulmonary arteriopathy implicates 
pulmonary endothelial cell injury as the event that leads to 
abnormal pulmonary vascular smooth muscle constriction 
and long-standing pulmonary hypertension. This finding 
lends support to the hypothesis that in primary pulmonary 
hypertension. plexogcnic pulmonary arteriopathy is a result 
of pulmonary endothelial injury. 
Recurrent Pulmonary Thromboembolism 
Etiology. Recurrent pulmonary thromboembolism is the 
histologic subtype that accounts for most of the remaining 
patients with primary pulmonary hypertension (3). The 
pathologic features include miliary embolization or throm- 
bosis in situ, followed by eccentric intimal proliferation and 
obliteration of the pulmonary vascular bed with the his- 
tologic demonstration of intravascular fibrous webs as evi- 
dence for either embolization or thrombosis in situ (30). The 
fact that pulmonary hypertension can be created in animals 
by the embolization of a variety of substances. with the 
amount of pulmonary hypertension related to the degree of 
embolization, supported the notion that recurrent microem- 
boli might be a mechanism for this disease (31). The obser- 
vation that some patients with recurrent pulmonary throm- 
boembolism have pulmonary hypertension is consistent with 
this concept (32). 
It has only recently been appreciated that, in addition to 
primary pulmonary hypertension. “thrombocmbolic” pul- 
monary hypertension may occur in patients with pre- 
tricuspid left to right congenital shunts, primarily atrial 
septal defects (33). Why an atrial septal defect would pro- 
duce miliary embolization in the lung has never been ade- 
quately addressed. In actuality. the data show that recurrent 
microembolization is highly unlikely to be the cause of 
primary or secondary pulmonary hypertension for several 
reasons. First, the number of emboli required to create 
severe pulmonary hypertension in vessels at the arteriolar 
level is enormous. In the dog, the number of emboli that 
would be needed to measure the pulmonary artery pressure 
by 5 to 10 mm Hg is between 90,000 and 22 million, which 
implies that a constant showering of emboli must be occur- 
ring (34). However. no source for miliary embolization has 
been documented in studies of patients with primary pulmo- 
nary hypertension (35). The histologic findings in patients 
with primary pulmonary hypertension with the “recurrent 
thromboembolism” pattern are also inconsistent with recur- 
rent embolization. as the predominant finding in these pa- 
tients is widespread severe eccentric intimal fibrosis (36). 
Although evidence for small vessel thrombosis exists, it is 
apparent in only approximately 10% of the vessels, clearly 
not enough to cause severe pulmonary hypertension (unpub- 
lished observations). 
Hypothesis: thromhotic pulmonary arteriopathy is a result 
of endothelial injury that produces a procoagulant environ- 
ment in the pulmonary vascular bed. Because there are no 
data supporting the concept of recurrent embolization as the 
cause of this syndrome, a more appropriate name would be 
“thrombotic pulmonary arteriopathy.” It has now been 
shown (37) that damage to vascular endothelium will result 
in an alteration of the environment for circulating platelets 
and thrombotic blood components rendering it susceptible to 
vascular thrombosis. Diffuse eccentric intimal proliferation, 
as a result of endothelial cell damage, with subsequent 
thrombosis as a result rather than a cause, would be a more 
logical pathophysiologic mechanism for thrombotic pulmo- 
nary arteriopathy. Patients with thrombotic pulmonary arte- 
riopathy have an intimal pattern that appears distinct from 
plexogenic arteriopathy. in which the predominant lesion is 
concentric laminar intimal fibrosis (30). In congenital heart 
disease, it is probable that high pulmonary blood flow and 
pressure over time, associated with high shear stress, results 
in one type of endothelial injury (i.e., ventricular septal 
defect and plexogenic arteriopathy). whereas high pulmo- 
nary blood flow without increased pressure and shear stress 
produces a different endothelial response (atria1 septal defect 
and thrombotic arteriopathy). The fact that pulmonary hy- 
pertension develops in only approximately 6% of patients 
with an atrial septal defect again suggests that some genetic 
predisposition is necessary (38). 
Types of pulmonary perfusion patterns. It would be help- 
ful to be able to determine the histologic subtype of primary 
pulmonary hypertension from clinical findings. We recently 
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studied patterns of perfusion lung scans in patients with 
primary pulmonary hypertension (39) and were able to 
distinguish two types of perfusion patterns: 1) normal, and 2) 
diffuse patchy perfusion abnormalities. Although it was 
originally thought that the latter represented a more severe 
form of vascular disease, the patterns appear to be distinct 
because the patients who have normal lung scans apparently 
never develop the patchy pattern as their pulmonary hyper- 
tension progresses. In this radiographic-pathologic study, 
we demonstrated that the patchy lung scan pattern, in 
association with a normal chest X-ray film, correlates with 
the thrombotic arteriopathic pattern and can be distin- 
guished from findings in patients with the plexogenic arte- 
riopathic pattern, who have a normal chest X-ray film and 
lung scan. With use of these clinical criteria, it appears that 
plexogenic arteriopathy is more likely to occur in young 
women, whereas thrombotic arteriopathy seems to have a 
similar prevalence in men and women of a slightly older age. 
Thrombosis in situ. That thrombosis in situ is occurring 
has now been confirmed. We recently studied (40) the sera of 
31 patients with primary pulmonary hypertension for the 
presence of fibrinopeptide A, a small peptide that is released 
by the action of thrombin with fibrinogen. We found a wide 
spectrum of values of fibrinopeptide A in our patients; in the 
majority, values were elevated several times above the 
normal value, suggesting an intense thrombotic state, with 
the highest levels in patients with the abnormal patchy lung 
scans. Fibrinopeptide A levels were brought toward normal 
after the administration of intravenous heparin, confirming 
that this is a biologically active peptide in these patients. The 
fact that they also had elevated levels of plasminogen 
activator inhibitor-l activity, but normal levels of cross- 
linked fibrin degradation products, suggests some type of 
acquired fibrolytic defect. Therefore, endothelial cell injury 
causing diffuse eccentric intimal proliferation and thrombo- 
sis in situ would seem to be the most scientifically sound 
explanation for this form of pulmonary hypertension. Data 
underscoring the importance of thrombosis was provided by 
Fuster et al. (41). who observed a salutary effect of warfarin 
anticoagulants on survival in a large number of patients with 
primary pulmonary hypertension studied retrospectively. 
From these observations, one could conclude that pri- 
mary pulmonary hypertension results from pulmonary endo- 
thelial injury, which leads either to intimal proliferation with 
smooth muscle hypcrtrophy (plexogenic pulmonary arteri- 
opathy) or to intimal proliferation with intravascular throm- 
bosis (thrombotic pulmonary arteriopathy). In primary pul- 
monary hypertension, as in other diseases, the histologic 
distinction between these two may not always be pure, and 
some overlap may exist. 
Pulmonary hypertension due to toxic oil ingestion. Re- 
cently, an epidemic of pulmonary hypertension due to toxic 
oil ingestion has been reported (42). After the ingestion of 
contaminated rapeseed oil in Spain in 1981. there was an 
outbreak of pulmonary hypertension that affected approxi- 
mately 1 in 1,000 exposed patients (once again raising the 
specter of an underlying genetic predisposition). Recent 
pathologic studies have shown that plexogenic pulmonary 
arteriopathy was the histologic finding in most patients, 
although some patients had coexisting thrombotic lesions 
and some had thrombotic pulmonary arteriopathy (43). The 
toxic oil syndrome is another clinical example of how an 
agent that produces acute pulmonary endothelial damage 
can result in plexogenic or thrombotic pulmonary arteriop- 
athy (perhaps dose related) or an overlap of the two. 
Therapeutic interventions. This Unitarian hypothesis on 
the pathogenesis of primary pulmonary hypertension pro- 
vides a clearer understanding of the limited success of 
therapeutic interventions. Warfarin anticoagulant therapy 
has been shown to be of probable benefit in some patients 
(41), whereas vasodilator drugs. primarily the calcium chan- 
nel blockers at high doses, appear to cause regression of 
right ventricular hypertrophy and possibly prolong survival 
in some patients (44). Although not yet demonstrated, it is 
reasonable to expect that the success of a particular form of 
therapy may correlate with the histologic subtype, anticoag- 
ulants for thrombotic arteriopdthy and vasodilators for plex- 
ogenic artcriopathy. This would apply not only to primary 
pulmonary hypertension, also to secondary forms of pulmo- 
nary hypertension that cause similar endothelial reactions. 
Nevertheless, the most common forms of secondary pulmo- 
nary hypertension, those caused by lung disease and left 
heart failure. do not appear to respond to vasodilators or 
anticoagulant therapy. They also do not appear to be asso- 
ciated with endothelial injury. They do seem to be quite 
treatable and even reversible. 
Pulmonary Venous Hypertension 
Mechanism. The histopathology of pulmonary venous 
hypertension shows primarily arterialization of the pulmo- 
nary venous bed, with secondary medial hypertrophy of the 
pulmonary arterioles and is only infrequently associated 
with concentric or eccentric intimal lesions (45). A classic 
example of this form of pulmonary hypertension is mitral 
stenosis. The observation has been made that pulmonary 
hypertension from mitral stenosis is reversible after mitral 
valve replacement, irrespective of the preoperative level of 
the pulmonary hypertension or elevation in pulmonary vas- 
cular resistance (46). Thus, by directing treatment toward 
the underlying mechanism. and in the absence of severe 
pulmonary endothelial damage, pulmonary venous hyper- 
tension is reversible. 
Therapy. Histologic examination of the lungs in patients 
with pulmonary hypertension from chronic obstructive pul- 
monary disease reveals the muscular arteries to have largely 
normal media and occasional eccentric intimal fibrosis. The 
predominant lesion is in the small arterioles, with severe 
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medial hypertrophy and longitudinal proliferation of muscle 
ceils that can infiltrate into the intima (45). Vasodilators 
appear to be ineffective in humans with hypoxic lung dis- 
ease, even though hypoxia seems to be one of the most 
potent stimuli for smooth muscle hypertrophy and vasocon- 
striction in the pulmonary vascular bed (47). Long-term 
oxygen therapy, in contrast, has been associated with im- 
proved survival and modest improvement in pulmonary 
hemodynamics (48). Thus, this other common form of sec- 
ondary pulmonary hypertension, also without evidence of 
extensive endothelial cell injury, seems to be treatable by 
reversing the offending etiologic agent. 
Conclusions 
Given these observations, we can propose a more sensi- 
ble approach toward our understanding of the origin of 
primary and secondary forms of pulmonary hypertension 
based on the nature of the pulmonary vascular damage, 
which may form the basis for developing more effective 
therapeutic regimens. The fact that vasodilators are not 
uniformly successful in primary or secondary pulmonary 
hypertension should not be considered as disappointing, but 
expected, given the heterogeneous nature of the diseases. 
The precise etiologic agents causing the endothelial cell 
damage in primary pulmonary hypertension have yet to be 
identified. However, as our understanding of the role of the 
endothelial cell in arterial vascular disease increases, more 
focused and effective treatments of pulmonary hypertensive 
states should be forthcoming. 
References 
I. Rich S. Primary pulmonary hypertension Prog Cardiovasc Die 1988: 
3:205-w 
2. Dresdale DT. Schultz M, Wlchtom RJ. Primary pulmonary hypertemion. 
I. Clinical and hemodynamic study. Am J Med 1951:11:686705. 
3. World Health OrganiTarion. Hatano S. Strasser T. eds. Primary Pulmo- 
nary Hypertension. Geneva: World Health Organization. 1975.7-45. 
4. Wagenvoort CA. Wagenvoort N. Takahashi T. Pulmonary venooccIusi\e 
dl$eaw: involvement of the pulmonary arteries and review of the litera- 
ture. Hum Pdthol 1985:16:1033-41. 
5. Lockhart A. Reeves JT. Plexogenic pulmonary hypertension of unknown 
origin: what’s new’ Clin Sci 1984,67:1-5. 
6. Yamaki S. Wagenvoort CA. Plexogenic pulmonary artertopathy: rlgnili- 
cance of medial thickness with respect to advanced pulmonary vascular 
lesions Am J Pathol 198l:lOS:7~~-(. 
7. Wagenroort CA. Wagenvoort K. Primary pulmonary hypertension: a 
pathologic study of the lung vessels in 156 clinically diagnosed cazes. 
Circulation 1970:47:ll6i-84. 
S. Dresdale PT. Michtom RJ. Schultz M. Recent studies m primary pulmo- 
nary hypertension including pharmacodynamic observation on pulmonary 
vascular resistance. Bull NY Acad Med 1954;30:195-207. 
9. Daoud FS. Reeves JT. Kelly DB. lsoproterenol as a potential pulmonary 
vasodilator m pl-unary pulmonary hypertension. Am J Cardml 197X: 
42:817-22. 
IO. Wood P Pulmonary hypertension with specral reference to the vasocon- 
strictive factor. Br Heart J 1958:X:557-70. 
I I. Hoffman JIE. Rudolph AM, Heymann MA. Pulmonary vascular disease 
wth congenital heart lesions: pathologic features and causes, Circulation 
1981:64:873-7. 
12. Wakaki K. Koirumi F. Fukase M. Vascular lesions in systemic lupus 
erythematosus (SLE) with pulmonary hypertension. Acta Pathol Jpn 
19X4:34:593604. 
13. Sullivan WD. Hunt DJ. Harmon CE, et al. A prospective evaluation 
emphasizing pulmonary involvement in patients with mixed connectwe 
tissue disease. Medicine 1984;63:92-107. 
14. Salerni R. Rodnan GP. Leon DF, et al. Pulmonary hypertension m the 
CREST syndrome variant of progressive systemic scleroses (sclero- 
derma). Arch Intern Med 1977:86:394-9. 
15. McDonnell PJ. Toye PA, Hutchins GM. Primary pulmonary hypertension 
and cirrhohis: are they related? Am Rev Respir Dis 1983;127:437-41. 
16. Bernthal AC. Eybel CE. Payne IA. Primary pulmonary hypertension 
after portacaval shunt. J Clin Gastroenterol 1983:5:363-6. 
17. Gurtner HP. Aminorex and pulmonary hypertension. Cor Vasa 1985: 
27:16&71. 
IS. Vanhoutte PM. The endothelium-modulator of vascular rmooth-muscle 
tone. N Engl J Med 1988:319:51?-3. 
19. Furchgott RF. Role of the endothelium in respon\eb of vascular smooth 
muscle. Circ Res 1983:53:557-73. 
10. DeMey JG. Gray SD. Endothelium-dependent reactivity in resistance 
\,essels. Prog Appl Microcirculation 1988:88:181--7. 
21. Peach MJ. Loeb AL. Smger HA, Saye J. Endothehum-derived vascular 
relaxing factor. Hypertension 1985;7(suppl 1):1-9&I-100. 
22. Furchgott RF. The requirement for endothelial cells in the relaxation of 
arteries by acetylcholine and some other vasodilators. Trends Pharmacol 
Sci 1981:2:1736. 
23. Rabinovitch M. Bothwell T. Hayakawa BN. et al. Pulmonary artery 
endothelial abnormalities in patients with congenital heart defects and 
pulmonary hypertension. Lab Invest 1986:55.632-53. 
24. Rabinovitch M. Andrew M. Thorn H. et al. .4bnormal endothelial factor 
VIII associated with pulmonary hypertension and congenital heart de- 
fects. Circulation 1987:76: 1043-52 
25. Miller VM. .Aarhus LL. Vanhoutte PM. Modulation of endothelium- 
dependent responses bv chrome alterations of blood flow Am J Phvsiol 
l986.?5l:H5?eH7. 
16. 
27. 
2x. 
29. 
3u. 
31. 
32 
33 
34. 
36. 
Hislop A. Reid L. Arterial changes in Crotalaria Spectabdis-induced 
pulmonary hypertension m rats. Br J Exp Pathol 1974;55:153-7. 
Meyrick B. Gamble W. Reid L. Development of Crotalaria pulmonary 
hypertension: hemodynamx and structural study. Am J Physiol 1980; 
!39:H692-9. 
Meyrxk B. Reid L. Development of pulmonary arterial changes in rats 
fed Crotalaria Spectabilis. .4m J Pathol 1979;94:37-48. 
Rich S. Kwas K. Hart K. et al. Antinuclear antibodies in primary 
pulmonary hypertension. J Am Coil Cardlol 1986:X:1307-I I. 
BJornsson J. Edwards WD. Primary pulmonary hypertension: a histo- 
pathologic study of 80 cases. Mayo Clin Proc 1985;60:1&25. 
Malik AB. Pulmonary microembolism. Physiol Rev 1983:63:lIl4-92 
Sharma GV. McIntyre KM. Sharma S. Sasahara AA. Clinical and 
hemodynamic correlates in pulmonary embolism. Clin Chest Med 1984: 
5:4?1-37. 
Yamaki S. Horwhl T. Miura M. ct al. Pulmonary vascular disease in 
\ecundum atrial septal defect wth pulmonary hypertension. Chest 1986: 
5:694-8. 
Dexter L. Smith CT. Quantitative studies of pulmonary embolism. Am J 
bled Sci 1964:247~641-8 
Rich S. I.evitsky S. Brundage BH. Pulmonary hypertension from chronic 
pulmonary thromboembolism Ann Intern Med 19X8:108:425-34. 
Edwards !V’. Pathology of pulmonary hypertension. Cardiowsc Chn 
1988:18:321-59. 
550 RICH AND BRUNDAGE 
BASIS OF PULMONARY HYPERTENSION 
37. Ryan US. The endothelial surface and responses to injury. Fed Proc 
1986:4S:101-8. 
38. Steele PM, Fuster V. Cohen M. et al. Isolated atrial septal defect with 
pulmonary vascular obstructive disease-long-term follow-up and predic- 
tion of outcome after surgical correction. Circulation 1987:76:1037-42. 
39. Rich S, Pietra CC. Kieras K. et al. Primary pulmonary hypertension: 
radiographic and scintigraphic patterns of histologic subtypes. Ann Intern 
Med 1986;105:499-502. 
40. Eisenberg PR. Rich S. Kaufmann L. et al. Evidence for increased 
thrombin activity in patients with primary pulmonary hypertension 
(abstr). Circulation 1987:76(suppl IV):IV-1246. 
41. Fuster V, Steele PM, Edwards WD. et al. Primary pulmonary hyperten- 
sion: natural htstory and the importance of thrombosis. Circulation 
1984;70:58&5. 
42. Tabuenca JM. Tonic-allergic syndrome caused by ingestion of rapeseed 
oil denatured with aniline. Lancet 1981:2:567-8. 
JACC Vol. 14, No. 3 
September 1989.545-50 
43. Gomez-Sanchez MA, Mestre de Juan M, Gomez-Pajuelo C. et al. 
Pulmonary hypertension due to toxic oil syndrome. Chest 1989;9S:325- 
31. 
44. Rich S. Brundage BH. High dose calcmm blocking therapy for primary 
pulmonary hypertension: evidence for long-term reduction in pulmonary 
arterial pressure and regression of right ventricular hypertrophy. Circu- 
lation 1987;76:135-41. 
45. Wagenvoort CA, Wagenvoort N. Pathology of Pulmonary Hypertenston. 
New York: John Wiley & Sons. 1977: l-290 
46. Zener JC. Hancock EW. Shumway NE, et al. Regression of extreme 
pulmonary hypertension and mitral valve surgery. Am J Cardiol 1972: 
30:82C-6. 
47. Fishman AP. Chronic car pulmonale. Am Kev Respir Dis 1976;114:775-9. 
48. Timms RM. Khaja FU. Williams GW. et al. Hemodynamic response to 
oxygen therapy in chronic obstructive pulmonary disease. Ann Intern 
Med 1985:103:29-36. 
